NDAORALTABLETPriority Review
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Mechanism of Action
Sphingosine 1-Phosphate Receptor Modulators
Pharmacologic Class:
Sphingosine 1-phosphate Receptor Modulator
Clinical Trials (5)
Repurposing Siponimod for Alzheimer's Disease
Started Aug 2025
105 enrolled
Alzheimer DiseaseMild Alzheimer DiseaseMCI With Increased Risk for Alzheimer Disease+1 more
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
Started Apr 2024
606 enrolled
Secondary Progressive Multiple Sclerosis
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
Started Apr 2023
113 enrolled
Relapsing Multiple SclerosisClinically Isolated SyndromeRelapsing Remitting Multiple Sclerosis+1 more
A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis
Started Nov 2022
210 enrolled
Secondary Progressive Multiple Sclerosis
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Started Jun 2022
134 enrolled
Active Secondary Progressive Multiple Sclerosis
Loss of Exclusivity
LOE Date
Apr 23, 2036
123 months away
Patent Expiry
Apr 23, 2036